Loading patent…
AssigneesAlloVir, Inc., Baylor College of Medicine, Wilson Wolf Manufacturing
InventorsRainer Ludwig Knaus, Katy Rebecca Newton, Juan Vera, Ann Leen, Cliona Rooney, John R. Wilson
Estimating the term…
An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.
An in vitro expansion process for rapid of antigen specific T cells, comprising culturing in a vessel comprising a gas permeable culture surface a population of PBMCs in a culture in the presence of an antigen, wherein the antigen is in the form of a peptide or a peptide mix relevant to a target antigen(s) and wherein the antigen is added to the culture in the range of from 1 to 500 ng per ml;
An in vitro process for rapid expansion of antigen specific T cells, comprising culturing in a gas permeable vessel a population of PBMCs in a culture in the presence of an antigen, wherein the antigen is in the form of a peptide or a peptide mix relevant to a target antigen(s) and wherein the antigen is added to the culture in the range of from 1 to 500 ng per ml;
An in vitro process for rapid expansion of antigen specific T cells, comprising culturing in a vessel comprising a gas permeable culture surface a population of PBMCs in a culture in the presence of an antigen, wherein the antigen is in the form of a peptide or a peptide mix relevant to a target antigen(s);
Dependencies are inferred from the claim text.